[go: up one dir, main page]

HUE053558T2 - Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében - Google Patents

Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében

Info

Publication number
HUE053558T2
HUE053558T2 HUE16806299A HUE16806299A HUE053558T2 HU E053558 T2 HUE053558 T2 HU E053558T2 HU E16806299 A HUE16806299 A HU E16806299A HU E16806299 A HUE16806299 A HU E16806299A HU E053558 T2 HUE053558 T2 HU E053558T2
Authority
HU
Hungary
Prior art keywords
adenosine
treatment
receptor ligand
fat accumulation
ectopic fat
Prior art date
Application number
HUE16806299A
Other languages
English (en)
Inventor
Pnina Fishman
Shira Cohen
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of HUE053558T2 publication Critical patent/HUE053558T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16806299A 2015-11-23 2016-11-22 Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében HUE053558T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL242723A IL242723B (en) 2015-11-23 2015-11-23 A3 adenosine receptor ligand for the treatment of ectopic fat accumulation

Publications (1)

Publication Number Publication Date
HUE053558T2 true HUE053558T2 (hu) 2021-07-28

Family

ID=57485841

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16806299A HUE053558T2 (hu) 2015-11-23 2016-11-22 Adenozin A3 receptor ligandum felhasználásra ektopikus zsírfelhalmozódás kezelésében

Country Status (19)

Country Link
US (2) US10780106B2 (hu)
EP (1) EP3380104B1 (hu)
JP (2) JP6980655B2 (hu)
KR (1) KR102103657B1 (hu)
CN (1) CN108367016B (hu)
BR (1) BR112018010391A8 (hu)
CA (1) CA3005961C (hu)
DK (1) DK3380104T3 (hu)
ES (1) ES2848150T3 (hu)
HR (1) HRP20210020T1 (hu)
HU (1) HUE053558T2 (hu)
IL (3) IL242723B (hu)
LT (1) LT3380104T (hu)
MX (1) MX378107B (hu)
PL (1) PL3380104T3 (hu)
PT (1) PT3380104T (hu)
RS (1) RS61372B1 (hu)
SI (1) SI3380104T1 (hu)
WO (1) WO2017090036A1 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) * 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in treatment
CN121045296A (zh) 2024-05-31 2025-12-02 康菲特生物制药有限公司 制备纳莫德诺森的工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU2002219497B2 (en) * 2001-01-16 2004-08-26 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
DE602007013359D1 (de) 2006-01-26 2011-05-05 Us Gov Health & Human Serv Allosterische a3-adenosin-rezeptormodulatoren
DK2227234T3 (da) * 2007-10-15 2014-08-11 Can Fite Biopharma Ltd Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf
CN104159589A (zh) * 2012-01-23 2014-11-19 坎-菲特生物药物有限公司 肝脏状况的治疗

Also Published As

Publication number Publication date
LT3380104T (lt) 2021-05-10
IL259396A (en) 2018-07-31
US11291681B2 (en) 2022-04-05
US20180264022A1 (en) 2018-09-20
CA3005961A1 (en) 2017-06-01
RS61372B1 (sr) 2021-02-26
MX378107B (es) 2025-03-10
IL289841B (en) 2022-07-01
EP3380104B1 (en) 2020-11-11
BR112018010391A8 (pt) 2019-02-26
PT3380104T (pt) 2021-02-05
WO2017090036A1 (en) 2017-06-01
DK3380104T3 (da) 2021-02-08
KR102103657B1 (ko) 2020-04-23
SI3380104T1 (sl) 2021-05-31
MX2018006026A (es) 2019-01-28
CN108367016B (zh) 2021-07-16
JP6980655B2 (ja) 2021-12-15
ES2848150T3 (es) 2021-08-05
IL259396B (en) 2022-02-01
JP6990934B2 (ja) 2022-01-12
IL242723B (en) 2019-12-31
US10780106B2 (en) 2020-09-22
EP3380104A1 (en) 2018-10-03
IL289841A (en) 2022-03-01
KR20180081595A (ko) 2018-07-16
JP2020090532A (ja) 2020-06-11
HRP20210020T1 (hr) 2021-03-05
JP2018534333A (ja) 2018-11-22
IL242723A0 (en) 2016-02-29
BR112018010391A2 (pt) 2018-11-21
CN108367016A (zh) 2018-08-03
US20200384009A1 (en) 2020-12-10
CA3005961C (en) 2024-06-04
PL3380104T3 (pl) 2021-08-02

Similar Documents

Publication Publication Date Title
EP3603596A4 (en) ABSORBENT PAD
IL256175A (en) Using exosomes to treat the disease
EP3374041A4 (en) TRAINING TREADMILL
DK3191144T3 (da) Medicinsk forbinding
DE112015002825A5 (de) Nicht-invasive Stoffanalyse
ITUB20159481A1 (it) Tappeto rotante manuale curvo
DK3474802T3 (da) Medicinsk forbinding
HUE055165T2 (hu) Inozit származékok patológiás kristályosodásban való alkalmazásra
EP3215219C0 (en) SKIN TREATMENT SYSTEM
DK3373874T4 (da) Medicinsk forbinding
IL289841A (en) A3 adenosine receptor ligand for use in the treatment of ectopic fat accumulation
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3309165A4 (en) SURFACE TREATMENT AGENT
EP3603593A4 (en) ABSORBENT TRIM
SI3248964T1 (sl) Tiazolovi modulatorji A3 adenozinskega receptorja
EP3309164A4 (en) SURFACE TREATMENT AGENT
CL2016000001S1 (es) Tela no tejida
EP3603595A4 (en) ABSORBENT PAD
IL255635A (en) Antiviral pharmaceutical composition for topical use
IT201700083527A1 (it) Tappetino
FR3043700B1 (fr) Non tisse
ES1180458Y (es) Salvamanteles
ITUB20152348A1 (it) Condimento per alimenti
UA30814S (uk) Масажний килимок
GB201706443D0 (en) Device for use in the assessment of peripheral arterial disease